Browsing Tag
GLP-1
48 posts
Why MedPal AI (AIM: MPAL) is betting on today’s oral Wegovy launch
Oral Wegovy launches in the UK today. MedPal AI just raised £5m and bought a care-home tech firm to try to ride the wave from day one.
DexCom (DXCM) gains strategic evidence edge as CONNECT study targets broader diabetes market
Find out how DexCom’s CONNECT study could expand CGM use in non-insulin Type 2 diabetes and reshape DXCM’s growth outlook.
Is Eli Lilly (LLY) building the obesity drug supply chain nobody else can easily match?
Lilly’s obesity pipeline needs industrial muscle. Its $4.5bn Indiana bet shows why manufacturing may decide the next GLP-1 race.
Magnum Ice Cream (NYSE: MICC) jumps 10.9% on Blackstone and CD&R takeover talk just five months after the Unilever spinoff
Magnum spun out of Unilever at 7.8 billion euros. Froneri sold at 15 billion. Blackstone and CD&R are watching. The summer ice cream season decides the bid.
How direct-to-patient delivery could become the next competitive edge in Europe’s GLP-1 race
Read how Novo Nordisk’s Wegovy delivery update could reshape Europe’s GLP-1 competition, pharmacy economics, and patient access strategy.
One pen, four doses, one month: Eli Lilly brings Zepbound KwikPen to Ro’s telehealth platform at $299
Eli Lilly (LLY) partners with Ro to launch the FDA-approved Zepbound KwikPen nationwide. What the $299 self-pay device means for the GLP-1 race. Read more.
Glenmark Pharmaceuticals (NSE: GLENMARK) launches GLIPIQ semaglutide in India at Rs 325 a week as generic GLP-1 era starts
Glenmark Pharmaceuticals launches GLIPIQ semaglutide in India from Rs 325 a week. Analysis of pricing, competition, and what it means for GLP-1 access. Read more.
HIMS near 52-week low as FDA issues 30 GLP-1 warning letters
FDA sends 30 warning letters to GLP-1 compounders, targeting Hims & Hers Health (HIMS) as regulatory and legal pressure intensifies. Read what it means for investors and the sector.
Cipla and Orbicular bring first generic liraglutide for obesity to U.S. market, targeting $127m opportunity
Cipla launches generic Saxenda (liraglutide) in the U.S. via partner Orbicular's FDA approval. What this means for GLP-1 generics competition, payers, and Cipla's peptide strategy. Read more.
Verdiva Bio advances VRB-101 into late-stage positioning with fully enrolled Phase 2b obesity study
Find out why Verdiva Bio’s Phase 2b enrollment milestone could determine whether once-weekly oral GLP-1 drugs can truly challenge injectables.